In agreement with what has been observed in melanoma patients (Hodis et al, 2012), we found that the dominating mutation in this cell line panel was BRAFV600E/K (34 of 49), whereas other mutations in BRAF, NRAS, or KRAS were less common (5/49, 8/49, and 1/49). This evidence concerns the gene NRAS and melanoma.